US-based Yingli Pharma, a company dedicated to developing drugs for both the Chinese and US markets, has announced that its drug linperlislib has been granted priority review status by the US Food and Drug Administration (FDA) for the treatment of adult patients with recurrent or refractory follicular lymphoma (FL) who have received at least two systemic treatments in the past, and adult patients with recurrent and/or refractory peripheral T/NK cell lymphoma who have received first-line sufficient treatment in the past. The priority review status is attributed to the drug being “eligible for conditional approval”.
Linperlislib: A Potent PI3Kδ Inhibitor
Linperlislib is a highly selective and potent PI3Kδ inhibitor that was conditionally approved to treat recurrent/refractory (R/R) follicular lymphoma (FL) in November last year. The drug is set to be co-promoted by Hengrui Medicine in China, expanding its reach and impact in the market.
Recognition and Support for Linperlislib
The drug has been recognized and included in the 2022 Shanghai Biomedical “New Excellent Drugs and Devices” List and the Shanghai First Recommended Batch Products List in 2023. These inclusions indicate municipal support for linperlislib, highlighting its potential as a valuable treatment option moving forward.-Fineline Info & Tech
